Breaking News

Simtra BioPharma Solutions Invests $14M to Expand Capabilities

Will enhance its ADC conjugation and purification clinical suite in Halle/Westfalen, Germany.

Author Image

By: Charlie Sternberg

Associate Editor

Simtra BioPharma Solutions, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, has announced a $14 million investment to expand its clinical-scale conjugation and purification capabilities for Antibody-Drug Conjugates (ADCs).   Set to be operational by late 2025, this expansion is part of Simtra’s strategy to build a comprehensive end-to-end service offering, from development to clinical and commercial fill/finish, accelerating time to market for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters